Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bayard R Huck

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Bioorganic & Medicinal Chemistry Letters|June 6, 2006
The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonistBayard R Huck, Luis Llamas, Michael J Robarge, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2022
Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352]Yufang Xiao, Bayard R Huck, Ruoxi Lan, et al.
Bioorganic & Medicinal Chemistry Letters|September 5, 2021
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitorsYufang Xiao, Bayard R Huck, Ruoxi Lan, et al.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Bioorganic & Medicinal Chemistry Letters|June 6, 2006
The design and synthesis of a tricyclic single-nitrogen scaffold that serves as a 5-HT2C receptor agonistBayard R Huck, Luis Llamas, Michael J Robarge, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2022
Corrigendum to "Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors" [Bioorgan. Med. Chem. Lett. 50 (2021) 128352]Yufang Xiao, Bayard R Huck, Ruoxi Lan, et al.
Bioorganic & Medicinal Chemistry Letters|September 5, 2021
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitorsYufang Xiao, Bayard R Huck, Ruoxi Lan, et al.
Journal of Medicinal Chemistry|August 2, 2019
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological DiseasesRichard D Caldwell, Hui Qiu, Ben C Askew, et al.
Pageof 2